Overview

Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
0
Participant gender:
All
Summary
Treatment Study to assess of safety and efficiency of conditioning with Plerixafor and G-CSF as additional agents for prevention of graft failure after transplantation in patients with chronic granulomatous disease
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Treatments:
JM 3100
Plerixafor
Criteria
Inclusion Criteria:

Patients aged ≥ 1 months and < 25 years Patients diagnosed with CGD eligible for an
allogeneic transplantation Signed written informed consent

Exclusion Criteria:

Lack of informed consent.